The treatments and prognoses of pelvic organ
carcinomas differ, depending on whether the primary
tumor originated in the rectum, urinary bladder, prostate, ovary, or uterus; therefore, it is essential to diagnose pathologically the primary origin and stages of these
tumors. To establish the panels of immunohistochemical markers for differential diagnosis, we reviewed 91 of the NCBI articles on these topics and found that the results correlated closely with those of the public protein database, the Human
Protein Atlas. The results revealed the panels of immunohistochemical markers for the differential diagnosis of rectal
adenocarcinoma, in which [+] designates positivity in rectal
adenocarcinoma and [-] designates negativity in rectal
adenocarcinoma: from bladder
adenocarcinoma, CDX2[+], VIL1[+], KRT7[-], THBD[-] and UPK3A[-]; from prostate
adenocarcinoma, CDX2[+], VIL1[+], CEACAM5[+], KLK3(PSA)[-], ACPP(PAP)[-] and SLC45A3(
prostein)[-]; and from ovarian
mucinous adenocarcinoma, CEACAM5[+], VIL1[+], CDX2[+], KRT7[-] and MUC5AC[-]. The panels of markers distinguishing ovarian serous
adenocarcinoma, cervical
carcinoma, and endometrial
adenocarcinoma were also represented. Such a comprehensive review on the differential diagnosis of
carcinomas of pelvic organs has not been reported before. Thus, much information has been accumulated in public databases to provide an invaluable resource for clinicians and researchers.